PDT Partners LLC Invests $1.28 Million in ADMA Biologics, Inc. (NASDAQ:ADMA)

PDT Partners LLC purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 63,859 shares of the biotechnology company's stock, valued at approximately $1,277,000.

A number of other hedge funds have also recently made changes to their positions in ADMA. Quest Partners LLC bought a new position in ADMA Biologics during the 2nd quarter worth approximately $29,000. Hollencrest Capital Management purchased a new stake in shares of ADMA Biologics during the third quarter valued at approximately $30,000. Larson Financial Group LLC bought a new position in shares of ADMA Biologics in the third quarter worth approximately $31,000. Harvest Fund Management Co. Ltd purchased a new position in shares of ADMA Biologics in the third quarter worth $62,000. Finally, CWM LLC increased its stake in shares of ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company's stock worth $92,000 after buying an additional 4,367 shares during the period. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Trading Down 2.1 %

Shares of ADMA traded down $0.42 during trading hours on Monday, reaching $19.69. 6,094,748 shares of the company traded hands, compared to its average volume of 3,633,505. ADMA Biologics, Inc. has a 12 month low of $3.60 and a 12 month high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company's fifty day moving average price is $19.07 and its two-hundred day moving average price is $15.47. The company has a market capitalization of $4.65 billion, a price-to-earnings ratio of 70.32 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period in the previous year, the firm posted $0.01 EPS. Equities research analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. HC Wainwright raised their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Raymond James raised their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th.

Insiders Place Their Bets

In other news, Director Lawrence P. Guiheen sold 9,000 shares of the business's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now directly owns 153,941 shares of the company's stock, valued at $2,843,290.27. The trade was a 5.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Brad L. Tade sold 15,000 shares of the company's stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the sale, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. The trade was a 7.00 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is owned by corporate insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.